Last reviewed · How we verify

NCT03944564: KOGIS

Cognitive and Motor Benefits of Standing

Status unknown NA Last updated 22 April 2021
What this trial tests

NA trial testing Sitting in Pain, Acute in 20 participants. Status unknown.

Timeline
10 September 2019
Primary endpoint
1 September 2022
1 September 2022

Quick facts

Lead sponsorScience and Research Centre Koper
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment20
Start date10 September 2019
Primary completion1 September 2022
Estimated completion1 September 2022
Sites1 location across Slovenia

Drugs / interventions tested

Conditions studied

Sponsor

Science and Research Centre Koper

Who can join

Adults 18 to 64, any sex, with Pain, Acute or Muscle Tone Abnormalities. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Upright-working has been proven to benefit health by combating the negative effects of physical inactivity. However, long-term commitment to static standing regimens may be limited due to symptoms of musculoskeletal fatigue that may develop during prolonged static standing in the absence of facilitated weight shifting. We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sitting

Trials testing the same drug.

Other recruiting trials for Pain, Acute

Currently open trials in the same condition.

Other Science and Research Centre Koper trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03944564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing